{"groups":[{"description":"Nirogacestat 150 mg by mouth, twice daily\n\nNirogacestat oral tablet: Nirogacestat tablet","id":"FG000","title":"Double-Blind Phase - Nirogacestat"},{"description":"Placebo by mouth, twice daily\n\nPlacebo Oral Tablet: Sugar pill manufactured to mimic nirogacestat 50 mg tablet","id":"FG001","title":"Double-Blind Phase - Placebo"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"14"},{"groupId":"FG001","numSubjects":"1"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Unqualified Clinical Progression"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"}],"type":"Participant non-compliance"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Not treated"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"11"}],"type":"Other reason"},{"reasons":[{"groupId":"FG000","numSubjects":"36"},{"groupId":"FG001","numSubjects":"23"}],"type":"Ongoing (still on treatment) pertains to treatment status at the time of the primary analysis"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"70"},{"groupId":"FG001","numSubjects":"72"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"69"},{"groupId":"FG001","numSubjects":"72"}],"type":"Treated (Safety Population)"},{"achievements":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"35"}],"comment":"Completed participants met the study endpoint. Information for completed and not completed pertains to treatment status at the time of the primary analysis. The open-label extension is ongoing.","type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"58"},{"groupId":"FG001","numSubjects":"37"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}